Stan Berenshteyn

Q: What is Stan Berenshteyn's success rate?

Stan Berenshteyn currently has a success rate of 97.68115039840637.

Q: What is the average return of Stan Berenshteyn's calls?

Their stock ratings have generated an average return of 7.522402231655634.

Wells Fargo | Healthcare

Stan Berenshteyn is an analyst from Wells Fargo specializing in the Healthcare sector. Ranked #1126 out of 4580 analysts, they have issued 24 stock ratings with a success rate of 97.68% and an average return of 7.52%.

Stan Berenshteyn has a well-established track record, with 24 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 97.68% and an average return of 7.52%, underscoring their expertise and ability to identify winning opportunities for investors.

#1126

Out of 4580

Total Ratings

+97.68%

Success Rate

+7.52%

Average Return

Recent Ratings Analysis

HCAT

Hold

Mar 18, 2026

Target

$1.00

Current

$1.17

Performance

—

Stan Berenshteyn rated HCAT as Equal-Weight on Mar 18, 2026, setting a price target of 1. The Hold stance appears justified, as shares hovered around 1.17 with a % move.

VEEV

Buy

Mar 05, 2026

Target

$333.00

Current

$186.70

Performance

—

On Mar 05, 2026, VEEV was given a Overweight rating by Stan Berenshteyn, with a target price of 333. The stock traded sideways with a % move, keeping the bullish thesis unresolved.

GDRX

Buy

Mar 04, 2026

Target

$7.00

Current

$2.23

Performance

—

GDRX received a Overweight rating from Stan Berenshteyn on Mar 04, 2026, aiming for 7. Price action was muted, as shares hovered around 2.23 despite the bullish outlook.

TDOC

Hold

Feb 26, 2026

Target

$8.00

Current

$5.61

Performance

4.86%

On Feb 26, 2026, Stan Berenshteyn published a Equal-Weight outlook on TDOC, with a target of 8. Sideways action left the Hold view intact, with no major move since 5.61.

CTEV

Hold

Feb 24, 2026

Target

$33.00

Current

$16.92

Performance

24.69%

Stan Berenshteyn on Feb 24, 2026 assigned CTEV a Equal-Weight rating, with a price target of 33. Shares outperformed expectations, climbing 24.69% despite the neutral view.

WAY

Buy

Feb 19, 2026

Target

$41.00

Current

$24.75

Performance

-4.03%

On Feb 19, 2026, Stan Berenshteyn reaffirmed WAY with a Overweight rating, targeting 41. Market indecision has kept the 41 target in a holding pattern.

DOCS

Buy

Feb 06, 2026

Target

$45.00

Current

$24.91

Performance

-10.17%

DOCS was rated Overweight by Stan Berenshteyn on Feb 06, 2026, with a price objective of 45. This case shows how bullish projections can fail, with the stock now below 24.91.

HNGE

Buy

Jan 09, 2026

Target

$68.00

Current

$44.11

Performance

-7.95%

On Jan 09, 2026, Stan Berenshteyn initiated coverage on HNGE with a Overweight rating and target of 68. The Buy call has yet to be validated as shares remain 23.89 away from the target.

PHR

Buy

Jan 09, 2026

Target

$30.00

Current

$11.19

Performance

-35.06%

Stan Berenshteyn issued a Overweight recommendation for PHR on Jan 09, 2026, price target set at 30. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

OMDA

Hold

Jan 09, 2026

Target

$17.00

Current

$14.62

Performance

-5.13%

On Jan 09, 2026, OMDA was evaluated by Stan Berenshteyn, who gave a Equal-Weight rating and target of 17. The Hold call avoided chasing into subsequent weakness of 5.13%.

OMCL

Buy

Jan 05, 2026

Target

$52.00

Current

$35.09

Performance

-25.23%

Stan Berenshteyn rated OMCL as Overweight on Jan 05, 2026, setting a price target of 52. The stock has underperformed, dropping 25.23% despite the bullish target of 52.

AMWL

Buy

Nov 05, 2025

Target

$9.00

Current

$5.60

Performance

22.54%

On Nov 05, 2025, AMWL was given a Overweight rating by Stan Berenshteyn, with a target price of 9. The stock rallied 22.54% after the rating, narrowing the gap to the target of 9 and validating the bullish stance.

HQY

Buy

Feb 26, 2025

Target

$125.00

Current

$79.40

Performance

-24.82%

HQY received a Overweight rating from Stan Berenshteyn on Feb 26, 2025, aiming for 125. The rating hasn’t played out as hoped, with the stock trading 24.82% below expectations.

ACCD

Hold

Oct 11, 2024

Target

$6.00

Current

$7.02

Performance

85.22%

On Oct 11, 2024, Stan Berenshteyn published a Equal-Weight outlook on ACCD, with a target of 6. The Hold call missed some of the bullish momentum as shares advanced toward 6.

Frequency Asked Questions

Who is Stan Berenshteyn?

Stan Berenshteyn is an analyst from Wells Fargo specializing in the Healthcare sector.

What is Stan Berenshteyn's success rate?

Stan Berenshteyn currently has a success rate of +97.68%.

How many ratings has Stan Berenshteyn issued?

Stan Berenshteyn has issued 24 stock ratings so far.

What is the average return of Stan Berenshteyn's calls?

Their stock ratings have generated an average return of +7.52%.

What is Stan Berenshteyn's ranking?

Stan Berenshteyn is ranked #1126 out of 4580 analysts.

What types of ratings does Stan Berenshteyn give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Stan Berenshteyn?

You can follow Stan Berenshteyn by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Stan Berenshteyn?

Their latest rating was a Hold on HCAT issued on 2026-03-18.